Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter July 27, 2010

Development and description of GETT: a Genetic testing Evidence Tracking Tool

International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) – IFCC Scientific Division Committee on Molecular Diagnostics

  • François Rousseau , Carmen Lindsay , Marc Charland , Yves Labelle , Jean Bergeron , Ingeborg Blancquaert , Robert Delage , Brian Gilfix , Michel Miron , Grant A. Mitchell , Luc Oligny , Mario Pazzagli , Cyril Mamotte , Deborah Payne and on behalf of the IFCC Scientific Division Committee on Molecular Diagnostics

Abstract

Background: The completion of the Human Genome Project has increased the pace of discovery of genetic markers for disease. Despite tremendous efforts in fundamental research, clinical applications still lag behind expectations, partly due to the lack of effective tools to systematically search for and summarize published data relative to the clinical assessment of new diagnostic molecular tests.

Methods: Through a collaborative process using published tools and an expert panel, we developed a detailed checklist of the evidence that needs to be collected or produced to evaluate the potential usefulness of a new molecular diagnostic test. This tool is called GETT, for Genetic testing Evidence Tracking Tool.

Results: GETT allows 1) researchers to summarize the current evidence and to identify knowledge gaps for further research and; 2) stakeholders to collect data related to a given molecular test and improve their decision-making process. GETT comprises 72 clearly defined items/questions, grouped into 10 categories and 26 sub-themes, including an overview of disease epidemiology and genetics, the available diagnostic tools, and their analytical and clinical performances, availability of quality control programs, laboratory and clinical best practice guidelines, clinical utility, and impact on health care and psycho-social, ethical and legal implications. It also includes a summary of the evidence available and attempts to prioritise knowledge gaps related to the testing. We also compare GETT to other existing frameworks.

Conclusions: This systematic evidence-based tracking tool, which is more detailed than existing frameworks and provides clear definition for each item, will help streamline collection of the available evidence to appraise the potential for clinical application of new molecular diagnostic tests and prioritize research to produce the evidence-base relative to the clinical implementation of molecular diagnostic tests.

Clin Chem Lab Med 2010;48:1397–407.


Corresponding author: François Rousseau, MD, MSc, FRCPC, Département de biologie moléculaire, biochimie médicale et pathologie, Faculté de Médecine, Université Laval, CRCHUQ-Hôpital St-François d'Assise, 10 rue de l'Espinay, Quebec, QC G1L 3L5, Canada Phone: +1 418-525-4470, Fax: +1 418-525-4429,

Received: 2010-4-21
Published Online: 2010-07-27
Published in Print: 2010-10-01

©2010 by Walter de Gruyter Berlin New York

Downloaded on 19.4.2024 from https://www.degruyter.com/document/doi/10.1515/CCLM.2010.291/html
Scroll to top button